Unlock instant, AI-driven research and patent intelligence for your innovation.

Alternative pathway-specific antibodies for the treatment of hemolytic disease

An antibody, paroxysmal technology, applied in blood diseases, cardiovascular system diseases, antibodies, etc., can solve problems such as lack of calcium ions

Active Publication Date: 2019-03-12
NOVELMED THERAPEUTICS
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] In Mg++ ions, but not with Ca ions, activation of the alternative pathway only guarantees AP activation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alternative pathway-specific antibodies for the treatment of hemolytic disease
  • Alternative pathway-specific antibodies for the treatment of hemolytic disease
  • Alternative pathway-specific antibodies for the treatment of hemolytic disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0335] Cell Assays to Demonstrate Inhibition of AP in Subjects Using Exemplary Compounds of a Class of Antibodies of the Invention activation

[0336] To assess the ability of exemplary compounds of the invention to inhibit AP activation in an in vivo-like system, an erythrocyte hemolysis assay was used. Rabbit red blood cells (rRBC) were incubated with normal human serum (NHS) in AP enabling buffer. The presence of rRBCs ("foreign bodies") preferentially induces the activation of APs, resulting in the deposition of C5b-9 on erythrocytes and ultimately cell lysis. The extent of cell lysis was detected based on light scattering at an optical density of 700 nm. Exemplary compounds of a class of antibodies of the invention inhibit rRBC hemolysis in a dose-dependent manner, as figure 2 and 3 shown.

[0337] Rabbit red blood cells (rRBC) were introduced into 10% human serum (with Mg 2+ / EGTA) indicates the introduction of a foreign cell surface that initiates the alternat...

Embodiment 2

[0342] Antibodies of the invention do not inhibit the classical pathway

[0343] To test the activity of the antibody for CP inhibition, antibody-sensitized sheep red blood cells (sRBC) were incubated in 1% normal human serum in CP buffer (Ca 2+ / Mg 2+ ) incubate. These sRBCs activate CP, which induces cell membrane lysis. Lysis of the cell membrane results in a progressive decrease in the light scattered by the cells. When the alternative pathway specific antibody of the present invention was mixed with sRBC in 1% NHS at 37°C and contained Ca 2+ and Mg 2+ No hemolysis was observed during the time period from the onset of hemolysis to the end of maximal hemolysis when incubated in a buffered agent ("CP buffer"). This indicates that the alternative pathway specific antibodies of the invention do not affect CP hemolytic activity in NHS ( Figure 5 ), and is not expected to impair the expected contribution of CP to host defense against pathogens.

[0344] The monoclonal ...

Embodiment 3

[0348] The antibodies of the invention do not inhibit the amplification process necessary for the full potential of the classical pathway

[0349]Candidate antibodies are tested for any inhibition of any amplification process that would affect the full potential of the canonical pathway using specifically referred assays. In this test, antigen-sensitized sheep red blood cells (sRBCs) were incubated in 10% normal human serum in CP buffer (Ca 2+ / Mg 2+ ) incubate. These sRBCs activate CP through antibody-antigen binding complexes, which induce lysis of the cell membrane. Lysis of cell membranes results in progressively less light scattered by intact cells. When the alternative pathway-specific antibody of the present invention is mixed with sRBC at 37°C in the presence of Ca 2+ and Mg 2+ When incubated in 10% normal human serum (NHS) with buffer ("CP buffer"), no hemolysis was observed during the time from the onset of hemolysis to the end of maximal hemolysis ( figure ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.

Description

[0001] related application [0002] This application claims priority from serial United States Provisional Patent Applications filed October 4, 2012, the contents of which are hereby incorporated by reference in their entirety. Background technique [0003] The complement system can be activated by 3 different enzymatic cascades called the "classical pathway", the "lectin / MBL" and the "alternative pathway" (CP, MBL and AP, respectively). This invention does not discuss MBL. The classical pathway is responsible for helping the host resist antigens, thereby preventing cells from becoming infected. The lectin pathway is a variant of the classical pathway. Where the initiator of complement activation is the classical pathway ("AP amplification loop"), the alternative pathway is currently thought to account for 80-95% of total complement activity. The alternative pathway itself is activated in a variety of disease states in which complement components are found to be elevated. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/40A61K39/395A61P7/04A61P35/00
CPCA61P7/00A61P7/02A61P7/04A61P9/10A61P13/02A61P35/00A61P43/00C07K16/18C07K2317/76C07K2317/565
Inventor R·班赛尔
Owner NOVELMED THERAPEUTICS